



# Medicines & Healthcare products Regulatory Agency

MHRA Central Freedom of  
Information Team  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU

[foi.request@mhra.gov.uk](mailto:foi.request@mhra.gov.uk)

[MHRA Website](https://www.mhra.gov.uk)

Our Ref: **FOI2024/00455**

4 September 2024

Dear [REDACTED]

Thank you for your Freedom of Information (FOI) request received on 17 August 2024. You wrote:

*Since you're insisting the Coronavirus vaccinations working, I would like you send me few studies on each of the vaccinations.*

*Such studies should consist of*

*Two groups, a vaccinated group and an unvaccinated group*

*A background of participants*

*How the vaccinations were administered?*

*The period of time the participants were monitored (six months at the very least)*

## MHRA Response

We can confirm that the Agency holds this information. However, the information is exempt under Section 21(1) of the Freedom of Information Act because the information is reasonably accessible to you, as it is already in the public domain.

Information on the studies submitted for the authorisation of each of the vaccines is available in the public domain through the Public Assessment Reports (PARs) that have been published by MHRA and the European Medicines Agency (EMA). Links to access the PARs for each of the vaccines authorised (Comirnaty, Vaxzevria, Spikevax, VidPrevtyn Beta and Nuvaxovid) are provided below:

### **Comirnaty**

<https://products.mhra.gov.uk/search/?search=Comirnaty&page=1&doc=Par&rerouteType=0>

<https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty>

### **Vaxzevria**

<https://products.mhra.gov.uk/search/?search=Vaxzevria&page=1&doc=Par&rerouteType=0>

<https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca>

### **Spikevax**

<https://products.mhra.gov.uk/search/?search=Spikevax&page=1&doc=Par&rerouteType=0>

<https://www.ema.europa.eu/en/medicines/human/EPAR/spikevax-previously-covid-19-vaccine-moderna>

**VidPrevtyn Beta**

<https://products.mhra.gov.uk/search/?search=Vidprentyn+Beta&page=1&doc=Par&rerouteType=0>

<https://www.ema.europa.eu/en/medicines/human/EPAR/vidprevtyn-beta>

**Nuvaxovid**

<https://products.mhra.gov.uk/search/?search=Nuvaxovid&page=1&doc=Par&rerouteType=0>

<https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid>

In addition to the above, the clinical data submitted for the authorisation of these vaccines is available through the EMA Clinical Data Repository. Access is free, through the creation of a free EMA account. A link to this repository is provided below:

<https://clinicaldata.ema.europa.eu/web/cdp/home>

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team  
Medicines & Healthcare products Regulatory Agency

---

**Your right to complain under the Freedom of Information Act**

If you are not happy with this response you may request an internal review by e-mailing [foi.request@mhra.gov.uk](mailto:foi.request@mhra.gov.uk) or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: [ICO FOI and EIR complaints](#) or telephone 0303 123 1113

**Re-use of our information**

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>